<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370370</url>
  </required_header>
  <id_info>
    <org_study_id>8533</org_study_id>
    <nct_id>NCT00370370</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab
      + triamcinolone acetonide in neovascular AMD.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual acuity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>central macular thickness</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leakage in fluorescein angiography</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraocular pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anterior chamber reaction</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Neovascular Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of intravitreal bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of bevacizumab + triamcinolone acetonide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Injection of intravitreal bevacizumab</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab + triamcinolone acetonide</intervention_name>
    <description>Injection of bevacizumab + triamcinolone acetonide</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cases of active neovascular AMD with visual acuity of 20/400- 20/40

        Exclusion Criteria:

          -  History of glaucoma or ocular hypertension

          -  Disciform scar
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Ahmadieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Center of Shaheed Beheshti Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamid Ahmadieh, MD</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2006</study_first_submitted>
  <study_first_submitted_qc>August 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2006</study_first_posted>
  <last_update_submitted>June 25, 2008</last_update_submitted>
  <last_update_submitted_qc>June 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2008</last_update_posted>
  <keyword>Bevacizumab,</keyword>
  <keyword>Triamcinolone</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Choroidal neovascular membrane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

